Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | DRD3 | P35462 | 13/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | HTR7 | P34969 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855316 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1AADRA2ADRD4 | |
| SCHEMBL1310960 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1AADRA2ADRD4 | |
| SCHEMBL20672353 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL29502145 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL3177580 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL30224993 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL1301816 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL3407353 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL28714263 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL28714264 | 0.99 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49110-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. | 2022-06-21 | — | — | US | claimed |
| US-20200375983-A1 | A PROCESS FOR THE PREPARATION OF CARIPRAZINE HYDROCHLORIDE | AUROBINDO PHARMA LTD (IN) | 2020-12-03 | — | — | US | claimed |
| CN-111320594-A | Carilazine impurity and preparation process and application thereof | 江苏恩华药业股份有限公司 | 2020-06-23 | — | — | CN | claimed |
| US-RE47333-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. (HU) | 2019-04-02 | — | — | US | claimed |
| US-9056845-B2 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. (HU) | 2015-06-16 | — | — | US | claimed |
| EP-2317852-B1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2014-12-24 | — | — | EP | claimed |
| EP-2358691-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE COMPOUNDS AND HYDROCHLORIDE SALTS THEREOF | RICHTER GEDEON NYRT (HU) | 2013-03-20 | — | — | EP | claimed |
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | RICHTER GEDEON NYRT. (HU) | 2010-01-21 | — | — | US | claimed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-RE49302-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. (HU) | 2022-11-15 | — | — | US | disclosed |
| US-RE49110-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. | 2022-06-21 | — | — | US | disclosed |
| US-20210300883-A1 | SYNTHESIS METHOD FOR CARIPRAZINE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210276965-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF CARIPRAZINE | RICHTER GEDEON NYRT. (HU) | 2021-09-09 | — | — | US | disclosed |
| WO-2010070371-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2010-06-24 | — | — | WO | disclosed |
| US-7737142-B2 | trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-methyl-urea, used in the therapy and/or prevention of pathological conditions requiring the modulation of dopamine receptors; high receptivity to dopamine receptors | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2010-06-15 | — | — | US | disclosed |
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | RICHTER GEDEON NYRT. (HU) | 2010-01-21 | — | — | US | disclosed |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-10-12 | — | — | US | disclosed |
| EP-1663996-A1 | (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005012266-A1 | (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | PRLHR, SLC6A3, SLC18A2 | DRD2 30/4885DRD3 93/4885HTR1A 17/4885 |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | DRD3, DRD2, TACR2 | DRD2 2/4885DRD3 1/4885HTR1A 172/4885 |
| US-20210300883-A1 | SYNTHESIS METHOD FOR CARIPRAZINE | AADAC, HDAC5, PDE12 | DRD2 684/4885DRD3 1145/4885HTR1A 1968/4885 |
| US-20200375983-A1 | A PROCESS FOR THE PREPARATION OF CARIPRAZINE HYDROCHLORIDE | ADRA2A, ADRA2C, HDAC2 | DRD2 68/4885DRD3 245/4885HTR1A 295/4885 |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | GPER1, GABRQ, GPR39 | DRD2 1191/4885DRD3 1822/4885HTR1A 167/4885 |
| US-20210276965-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF CARIPRAZINE | PAICS, AADAC, DDC | DRD2 992/4885DRD3 1286/4885HTR1A 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.